Other Vaccines - Southeast Asia

Southeast Asia

Highlights

In Southeast Asia, the revenue in the Other Vaccines market is projected to reach US$573.60m in 2024.
It is expected that the revenue will show an annual growth rate (CAGR 2024-2029) of 11.07%, resulting in a market volume of US$969.70m by 2029.
When compared globally, United States is expected to generate the most revenue in this market, with US$24.73bn in 2024.
The demand for other vaccines in Southeast Asia is rising due to increasing awareness about the importance of preventive healthcare.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The demand for vaccines in Southeast Asia is on the rise, with the Other Vaccines market experiencing significant growth in recent years.

Customer preferences: Customers in Southeast Asia are becoming increasingly aware of the importance of vaccines in preventing diseases and are more willing to invest in preventative healthcare. This is particularly true for diseases that are endemic in the region, such as dengue fever and Japanese encephalitis. Additionally, the COVID-19 pandemic has highlighted the importance of vaccines and has led to an increased demand for all types of vaccines.

Trends in the market: The Other Vaccines market in Southeast Asia is expected to continue to grow in the coming years. This growth is being driven by several factors, including the increasing awareness of the importance of vaccines, the rising incidence of diseases such as dengue fever and Japanese encephalitis, and the ongoing COVID-19 pandemic.

Local special circumstances: In Indonesia, the government has launched an immunization program to combat the high incidence of dengue fever in the country. This program has led to an increase in demand for the dengue fever vaccine in the country. In the Philippines, the government has implemented a vaccination program for Japanese encephalitis, which has also led to an increase in demand for the vaccine.

Underlying macroeconomic factors: The growing middle class in Southeast Asia is driving demand for healthcare services, including vaccines. Additionally, governments in the region are investing in healthcare infrastructure and are implementing programs to improve access to healthcare services. These factors are expected to continue to drive growth in the Other Vaccines market in Southeast Asia in the coming years.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.